Palbociclib and Breast Cancer Therapy

Palbociclib has several direct competitors currently on the market or in clinical trials. In September 2017, abemaciclib , another selective CDK4/6 inhibitor owned and manufactured by Eli Lilly , was approved for HR-positive, HER2-negative advanced metastatic breast cancer both in combination with fulvestrant and as a monotherapy . In March 2017, the FDA also approved ribociclib , owned by Novartis , as a combination therapy with aromatase inhibitors for indications similar to those of palbociclib and ribociclib.

发表评论

电子邮件地址不会被公开。 必填项已用*标注

Sections

Shows

Local News

Tools

About Us

Follow Us

跳至工具栏